NCT00089427View on ClinicalTrials.gov

IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

July 31, 2007

Conditions
Glioblastoma MultiformeAnaplastic AstrocytomaOligoastrocytoma
Interventions
DRUG

IL13-PE38QQR

PROCEDURE

Surgery for placement

PROCEDURE

Radiation therapy

DRUG

Temozolomide with radiation therapy

Trial Locations (6)

22908

University of Virginia Health Systems - Department of Neurological Surgery, Charlottesville

27710

Duke University Medical Center, Durham

28204

Carolina Neurosurgery & Spine Assoc., Charlotte

44195

Cleveland Clinic Foundation Department of Neurological Surgery, Cleveland

77030

University of Texas M.D. Anderson Cancer Center, Houston

94143

University of California San Francisco - Dept. of Neurological Surgery, San Francisco

Sponsors
All Listed Sponsors
lead

INSYS Therapeutics Inc

INDUSTRY

NCT00089427 - IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma | Biotech Hunter | Biotech Hunter